Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Email alerts

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Published

Psychopathological descriptive model of hallucinogenic/psychedelic drugs effect in the treatment of depression and addictions

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal
European psychiatry: the journal of the Association of European Psychiatrists
Date
2022-09-01
Source
Europe PMC
DOI
Unavailable
PubMed
Unavailable

Authors

Girala N.
Watch author

Derived topics and classifications

psilocybin DepressionAddictionEmotional ProcessingMystical ExperienceReview Article Review Article

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Exploring the Therapeutic Potential of Psilocybin: A Comprehensive Review of Clinical Trial Evidence and Implications for Rescheduling.Mini reviews in medicinal chemistry · 2026-09-18Through the Looking-Glass: A Scoping Review of Psychological Mechanisms of Psychedelic-Assisted Therapy for Substance Use DisordersCurrent Addiction Reports · 2026-09-02Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's DiseaseClinicalTrials.gov · 2026-09-30ADEPT: Augmenting DBT Effectiveness With Psilocybin-Assisted TherapyClinicalTrials.gov · 2026-09-22Implications of Potential US FDA Approval of Psychedelics or Psychedelic-Adjacents Such as Ibogaine for Pharmacy in Japan.Cureus · 2026-09-13Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCDFrontiers in Psychiatry · 2026-09-08Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]ClinicalTrials.gov · 2026-09-02Age and Cannabis Co-Use Are Associated with Differences in Experience and Perceived Benefits of Psilocybin: A Retrospective Study.Journal of psychoactive drugs · 2026-09-02